Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
23 Oct 2019
Historique:
received: 12 03 2019
accepted: 20 09 2019
entrez: 25 10 2019
pubmed: 28 10 2019
medline: 27 2 2020
Statut: epublish

Résumé

Leptomeningeal metastasis (LM) is a predominantly late stage, devastating complication of a variety of malignant solid tumors. Diagnosis relies predominantly on neurological, radiographic, and cerebrospinal fluid (CSF) assessments. Recently, liquid biopsy tests derived from CSF has shown to be a feasible, noninvasive promising approach to tumor molecular profiling for proper brain cancer diagnostic treatment, thereby providing an opportunity for CSF-based personalized medicine. However, LM is typically misleadingly assumed to originate from only one primary tumor type. In this case report, we provide first evidence of the co-occurrence of LM originating from more than one primary tumor types. Based on this patient case profile, the co-occurrence of LM from two or more primary tumor types should be accounted for when deriving diagnostic conclusions from liquid biopsy tests.

Sections du résumé

BACKGROUND BACKGROUND
Leptomeningeal metastasis (LM) is a predominantly late stage, devastating complication of a variety of malignant solid tumors. Diagnosis relies predominantly on neurological, radiographic, and cerebrospinal fluid (CSF) assessments. Recently, liquid biopsy tests derived from CSF has shown to be a feasible, noninvasive promising approach to tumor molecular profiling for proper brain cancer diagnostic treatment, thereby providing an opportunity for CSF-based personalized medicine. However, LM is typically misleadingly assumed to originate from only one primary tumor type.
CASE PRESENTATION METHODS
In this case report, we provide first evidence of the co-occurrence of LM originating from more than one primary tumor types.
DISCUSSION AND CONCLUSIONS CONCLUSIONS
Based on this patient case profile, the co-occurrence of LM from two or more primary tumor types should be accounted for when deriving diagnostic conclusions from liquid biopsy tests.

Identifiants

pubmed: 31646997
doi: 10.1186/s12885-019-6183-2
pii: 10.1186/s12885-019-6183-2
pmc: PMC6813083
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

995

Références

Ochsner J. 2017 Winter;17(4):362-378
pubmed: 29230121
Cancer. 1978 Aug;42(2):660-8
pubmed: 679158
Surg Neurol Int. 2013 May 02;4(Suppl 4):S265-88
pubmed: 23717798
World J Gastroenterol. 2014 Feb 28;20(8):2120-6
pubmed: 24587686
J Gastrointest Oncol. 2015 Dec;6(6):E89-E101
pubmed: 26697206
Oncogene. 2015 Mar 19;34(12):1608
pubmed: 25790189
Semin Oncol. 2009 Aug;36(4 Suppl 2):S46-54
pubmed: 19660683
Eur J Cancer. 2018 May;95:75-84
pubmed: 29635147
Cancer Treat Rev. 2016 Feb;43:83-91
pubmed: 26827696
Lancet Neurol. 2006 May;5(5):443-52
pubmed: 16632315
J Clin Neurosci. 2016 May;27:130-7
pubmed: 26778048

Auteurs

Ann-Kathrin Stoppek (AK)

Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
West German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
German Cancer Consortium, Partner Site University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Sied Kebir (S)

Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
West German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
German Cancer Consortium, Partner Site University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
DKFZ Division of Translational Neurooncology at the West German Cancer Center (WTZ); German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Andreas Junker (A)

Institute of Neuropathology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Kathy Keyvani (K)

Institute of Neuropathology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Stefan Zülow (S)

Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.

Lazaros Lazaridis (L)

Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
West German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
German Cancer Consortium, Partner Site University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Teresa Schmidt (T)

Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
West German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
German Cancer Consortium, Partner Site University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Daniela Pierscianek (D)

West German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
German Cancer Consortium, Partner Site University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
Department of Neurosurgery, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Martin Stuschke (M)

Department of Radiotherapy, University Hospital Essen, Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Ulrich Sure (U)

West German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
German Cancer Consortium, Partner Site University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
Department of Neurosurgery, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Christoph Kleinschnitz (C)

Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Björn Scheffler (B)

DKFZ Division of Translational Neurooncology at the West German Cancer Center (WTZ); German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.

Lisa Zimmer (L)

West German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
German Cancer Consortium, Partner Site University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
Department of Dermatology, University Hospital, University Duisburg-Essen, Germany & German Cancer Consortium (DKTK), Heidelberg, Germany.

Martin Glas (M)

Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. Martin.Glas@uk-essen.de.
West German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany. Martin.Glas@uk-essen.de.
German Cancer Consortium, Partner Site University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany. Martin.Glas@uk-essen.de.
DKFZ Division of Translational Neurooncology at the West German Cancer Center (WTZ); German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany. Martin.Glas@uk-essen.de.
Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. Martin.Glas@uk-essen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH